A recent study is looking at the breast cancer subtype which is dangerous and is called “HER2-positive”. This is found to affect about one patient out of four. This is a disease wherein the tumor cells happen to over express a signaling protein which is called HER2. This study claims to have the answer to treat this aggressive form of breast cancer.
Women suffering from HER2-positive breast cancer use Herceptin as a treatment, but the medicine happen to stop working after a few years because it is resistant to the treatment. According to doctors the prognosis for patients is worse in HER2-positive breast cancer than from the other subtype of the illness.
A multi-institution team led by CSHL Professor Nicholas Tonks has found a means of inhibiting another protein that is up-regulated in HER2-positive breast cancer. The protein is known as PTP1B and it can play a critical role in developing tumors that would resonate HER2 signaling.
The researchers treated mice by modeling HER2-positive breast cancer that had a PTP1B inhibitor names MSI-1436. This was then inhibited signaling by HER2 proteins. This PTP1B was discovered by Dr. Tonks about 25 years ago.
This study was published online in the journal Nature Chemical Biology.
Read more on Health News
-1751527287915.png)
-1751352905978.jpg)
